Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Switzerland
/
Pharmaceuticals & Biotech
Create a narrative
Galderma Group Community
SWX:GALD Community
1
Narratives
written by author
0
Comments
on narratives written by author
10
Fair Values set
on narratives written by author
Create a narrative
Galderma Group
Popular
Undervalued
Overvalued
Community Investing Ideas
Galderma Group
AN
AnalystConsensusTarget
Consensus Narrative from 11 Analysts
Nemluvio Launch And Global Expansion Will Shape Therapeutic Dermatology Markets
Key Takeaways Launch of Nemluvio and international expansion in China and India are expected to significantly boost revenue growth and market share. E-commerce strategy and market demand for Injectable Aesthetics are likely to improve net margins and sustain sales momentum.
View narrative
CHF 108.71
FV
6.0% undervalued
intrinsic discount
13.26%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
6
users have followed this narrative
13 days ago
author updated this narrative
Your Valuation for
GALD
GALD
Galderma Group
Your Fair Value
CHF
Current Price
CHF 102.20
2.7% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-97m
8b
2015
2018
2021
2024
2025
2027
2030
Revenue US$7.7b
Earnings US$402.7m
Advanced
Set Fair Value